Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Patient identification Platform (Patient iP) announced a new partnership with Aprima Medical Software.
read more
PathoQuest has received GLP certificate of conformity following a successful inspection by the French National Agency for Medicine and Health Products Safety (ANSM).
read more
Wednesday, October 27, 2021
PathoQuest, a pioneer in the quality control of biologics using Next-Generation Sequencing (NGS), announced today that it has been awarded €0.85M from the French Investment Program for the Future (Programme d’Investissement d’Avenir - PIA 4). This ...
read more
Wednesday, December 09, 2020
PathoQuest has received support from the Île-de-France region as part of the PM’up Relance Industrie program to accelerate the industrialization of the company’s high value-added service for quality control testing of biologics.
read more
Wednesday, November 24, 2021
PathoQuest, a contract research organization (CRO) for the biosafety testing of biologics with Next-Generation Sequencing (NGS) technologies, today announced that it has obtained a Good Manufacturing Practices (GMP) certificate for its quality ...
read more
Wednesday, December 23, 2015
Pathline Emerge Pathology Services announced the latest feature expansion of their Clinical Data Exchange capabilities by entering into a definitive agreement with Halfpenny Technologies Inc. The HTI platform will work in conjunction with their ...
read more
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that it continues to implement its corporate transformation strategy across its commercial and pharmaceutical ...
read more
Patheon announced it expects to invest approximately $45 million at key sites across its global network to meet growing customer demand for expanded service capabilities.
read more
Thursday, September 05, 2013
Patheon Inc., a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, will be hosting a complimentary seminar on “Robustness, Reproducibility and Risk Management; the Route to Successful...
read more
Tuesday, November 29, 2016
Patheon has signed a definitive agreement to acquire a state-of-the-art active pharmaceutical ingredients (API) manufacturing facility in Florence, South Carolina, from Roche Holdings, Inc., an indirect, wholly owned subsidiary of Roche Holding Ltd.,...
read more
Wednesday, October 31, 2012
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, today announced that it has entered into a definitive agreement with VION N.V., a global manufacturer of foodstuffs and ...
read more
Patheon, a global provider of pharmaceutical development and manufacturing services, has signed a manufacturing agreement with Amgen, one of the world’s leading biotechnology companies, headquartered in Thousand Oaks, CA.
read more
Monday, February 22, 2016
Patheon, a global provider of pharmaceutical development and manufacturing services has announced it has signed a strategic agreement with Grünenthal, an independent, family-owned, international research-based pharmaceutical group headquartered in ...
read more
Patheon reported financial results for the quarter ended April 30, 2017.
read more
Patheon, a global provider of pharmaceutical development and manufacturing services, has reported financial results for the quarter ended January 31, 2017.
read more